Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Recruiting now

Conditions studied: Moderate-to-severe Plaque Psoriasis

In brief

The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.

Key facts

Study ID

NCT06258668

Run by

Bristol-Myers Squibb

People needed

505

Starts

2024-08-21

Expected to finish

2028-09-30

Last updated by the study team

2024-11-06

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult participants ≥19 years of age
• Diagnosis of moderate-to-severe plaque psoriasis
• Candidate for phototherapy or systemic therapy
• Will begin deucravacitinib according to approved product label

You may not qualify if…

• Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
• Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)

Where it is running

• Novotech Laboratory Korea Co., Ltd. — Seoul, South Korea (enrolling)
• Local Institution - 0001 — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.